DIAN‐TU‐001 Trial (Tau NexGen) Rationale and Enrollment Experience
This trial will investigate potential benefits of anti-tau etalanetug with lecanemab, given as background therapy.
Authors
- Shobha Dhadda (ORCID: https://orcid.org/0000-0002-7290-7168)
- Eric McDade (ORCID: https://orcid.org/0000-0002-6764-3866)
- Jorge J. Llibre‐Guerra (ORCID: https://orcid.org/0000-0002-2137-7750)
- Lon S. S Schneider
- Guoqiao Wang
- Susan Mills
- Randall J. Bateman
- David B. Clifford
- Brian A. Gordon
- Tammie L.S. Benzinger
- Larisa Reyderman
- Michael C. Irizarry
- David Li
Institutions
- University of Southern California (US)
- Washington University in St. Louis (US)
- Keck Hospital of USC (US)
- Eisai (United States) (US)
- Banner Alzheimer’s Institute
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_105298
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00